Bristol Myers Squibb (BMY) reported first-quarter earnings that exceeded Wall Street expectations, driven by strong growth in key pharmaceuticals like Eliquis and newer cancer therapies. The company posted adjusted earnings of $1.58 per share, surpassing the analyst consensus of $1.42, while revenue reached $11.49 billion...
Bristol-Myers Squibb (BMY) shares gained momentum following the release of positive two-year clinical trial data for its immunology drug Sotyktu in psoriatic arthritis. The Phase 3 POETYK PsA-2 study and its open-label extension demonstrated durable efficacy and a consistent safety profile, with results presented at...
Erste Group Bank analyst H. Engel has lowered its full-year 2027 earnings per share (EPS) forecast for Bristol Myers Squibb to $6.10, down from a previous estimate of $6.12. This adjustment places the company below the broader consensus estimate of $6.34. The report was issued...
BioNTech and Bristol Myers Squibb have announced encouraging interim Phase 2 data from the global ROSETTA Lung-02 clinical trial for pumitamig, a PD-L1xVEGF-A bispecific immunomodulator. The combination of pumitamig with chemotherapy demonstrated robust antitumor activity in patients with previously untreated advanced non-small cell lung cancer...
Bristol-Myers Squibb (BMY) shares recently closed at US$63.88, trading below a Discounted Cash Flow (DCF) model's estimated intrinsic value. The company generated approximately $11.5 billion in free cash flow over the last twelve months, with forecasts projecting a mature profile featuring an initial step-up followed...
On September 1, 2026, Bristol-Myers Squibb (BMY) paused enrollment in its competing CAR-T program, zola-cel, for autoimmune and neurological conditions. The company cited precautionary measures following observations of 'transient and reversible' inflammatory events, explicitly noting that no patient deaths occurred during this period. Unlike Novartis,...
Bristol Myers Squibb (BMY) shares traded on the NYSE on September 25, 2026, closing at USD 61.93, representing a gain of 0.71 percent or USD 0.43 from the prior session's reference price. The stock opened at USD 61.75 and fluctuated between an intraday low of...
The article compares Bristol Myers Squibb (BMY) and Pfizer, noting BMY's focus on oncology and immunology versus Pfizer's transformation into high-growth areas like obesity. In fiscal year 2025, BMY reported revenue of nearly $48.2 billion, a slight decline of 0.2%, with net income of approximately...
Bristol-Myers Squibb (BMY) shares closed at USD 62.84 on September 17, 2026, trading approximately 8.4% below their 52-week high but well above the low. The company reported strong second-quarter 2026 financial performance with revenue rising 5.7% year-over-year and achieving a profit margin of 25.57%. These...
Bristol-Myers Squibb (BMY) shares closed at USD 62.84 on September 17, 2026, reflecting a mixed market reaction where strong second-quarter financial performance was partially offset by the decision to halt development of the oncology candidate ORM-6151. The company reported Q2 2026 revenue of USD 12.97...
Bristol Myers Squibb (BMY) reported strong quarterly financial results, beating analyst expectations with earnings per share of $2.04 against a consensus of $1.60 and revenue rising 5.7% year-over-year to $12.97 billion. The company maintains a robust balance sheet with a quick ratio of 1.38 and...
Nykredit A/S purchased 506,199 shares of Bristol Myers Squibb (BMY) in the second quarter, valued at approximately $29.2 million, contributing to institutional ownership of 76.41%. The company reported strong quarterly financials with earnings per share of $2.04, beating estimates of $1.60, and revenue rising 5.7%...
Simply Wall St analysis suggests Bristol-Myers Squibb (BMY) stock is undervalued by approximately 46.3%, trading at $63.83 per share against a Discounted Cash Flow (DCF) intrinsic value estimate of roughly $119. The company has delivered a 38.1% gain over the past year, yet valuation metrics...
Janney Montgomery Scott LLC increased its stake in Bristol Myers Squibb (NYSE:BMY) by 6.8% in the first quarter, purchasing 49,310 shares to bring total holdings to 770,244 shares valued at approximately $46.7 million. Other institutional investors also adjusted positions, with Horizon Bancorp increasing its stake...
Bristol Myers Squibb reported solid first-quarter results with total revenue of approximately $11.5 billion, representing a 1% year-over-year increase, while its growth portfolio expanded by 9% to reach $6.2 billion. Key performers included Breyanzi, which grew 53%, and Camzyos, whose revenue nearly doubled to $314...
Bristol Myers Squibb (BMY) shares closed at USD 63.88 on September 28, 2026, representing a gain of USD 1.02 or 1.62% from the previous session's close of USD 62.86. The stock traded on the New York Stock Exchange as of 20:00:02 UTC. On September 25,...
Bristol Myers Squibb (BMY) reported second-quarter 2026 financial results that exceeded market consensus, driving a modest 0.1 percent gain in its share price to close at USD 62.68 on the NYSE. The company posted quarterly earnings per share of USD 2.04, significantly beating the USD...
Bristol Myers Squibb (NYSE: BMY) reported encouraging mid-stage trial results for its experimental CAR-T cell therapy, arlo-cel, in patients with advanced multiple myeloma who have exhausted four prior treatment classes. The therapy met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement...
Bristol-Myers Squibb (NYSE:BMY) is highlighted as a top-tier cash-rich dividend stock, ranking second on a list of eight such companies. The article notes that corporate cash reserves have reached an all-time high of $4.11 trillion in Q1 2024, driven by strong economic conditions and elevated...
Hudson Edge Investment Partners Inc. reduced its stake in Bristol Myers Squibb (NYSE:BMY) by 17.7% during the first quarter, selling 29,888 shares to hold a remaining position of 138,879 shares valued at $8.42 million. This reduction brings BMY to 1.2% of Hudson Edge's total holdings,...
